Journal
TRENDS IN CANCER
Volume 8, Issue 2, Pages 135-144Publisher
CELL PRESS
DOI: 10.1016/j.trecan.2021.11.007
Keywords
-
Categories
Funding
- Jacquelyn A. Brady Fund
- NIH [R01CA242845]
- Cancer Prevention and Research Institute of Texas [RP1100584]
- Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy [1U01 CA180964]
- NCATS [UL1 TR000371]
- MD Anderson Cancer Center Support Grant [P30 CA016672]
Ask authors/readers for more resources
Tissue-agnostic drug development provides new treatment options for rare tumors, but challenges remain due to heterogeneous nature and failed clinical trials in sarcomas. Approvals for neurotrophic tyrosine receptor kinase (NTRK) fusion, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) phenotype, and tumor mutation burden-high (TMB-H) status are particularly important in sarcomas. Future research may focus on tissue-agnostic targets such as rearranged during transfection (RET), fibroblast growth factor receptor (FGFR), and neuregulin-1 (NRG1).
Tissue-agnostic drug development is a major step forward in offering treatment options for rare tumors. Sarcomas are heterogeneous rare malignancies with more than 100 subtypes. Recent failure of Phase III trials, nonbiomarker-driven clinical trials, and rarity hamper developmental therapeutics in sarcomas. Since a 'one-size-fits-all' approach continues to be the standard of care, tissue-agnostic approvals assume significance in sarcomas. In this review, we focus on the clinical evidence of recent drug approvals for neurotrophic tyrosine receptor kinase (NTRK) fusion, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) phenotype, and tumor mutation burden-high (TMB-H) status in the context of sarcomas, and the future landscape of tissueagnostic targets, such as rearranged during transfection (RET), fibroblast growth factor receptor (FGFR), and neuregulin-1 (NRG1).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available